OtherClinical Investigations
Bone Metastases in Carcinoid Tumors: Clinical Features, Imaging Characteristics, and Markers of Bone Metabolism
Wim G. Meijer, Eveline van der Veer, Piet L. Jager, Erik J. van der Jagt, Bert A. Piers, Ido P. Kema, Elisabeth G.E. de Vries and Pax H.B. Willemse
Journal of Nuclear Medicine February 2003, 44 (2) 184-191;
Wim G. Meijer
Eveline van der Veer
Piet L. Jager
Erik J. van der Jagt
Bert A. Piers
Ido P. Kema
Elisabeth G.E. de Vries
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Bone Metastases in Carcinoid Tumors: Clinical Features, Imaging Characteristics, and Markers of Bone Metabolism
Wim G. Meijer, Eveline van der Veer, Piet L. Jager, Erik J. van der Jagt, Bert A. Piers, Ido P. Kema, Elisabeth G.E. de Vries, Pax H.B. Willemse
Journal of Nuclear Medicine Feb 2003, 44 (2) 184-191;
Bone Metastases in Carcinoid Tumors: Clinical Features, Imaging Characteristics, and Markers of Bone Metabolism
Wim G. Meijer, Eveline van der Veer, Piet L. Jager, Erik J. van der Jagt, Bert A. Piers, Ido P. Kema, Elisabeth G.E. de Vries, Pax H.B. Willemse
Journal of Nuclear Medicine Feb 2003, 44 (2) 184-191;
Related Articles
- No related articles found.
Cited By...
- Bone metastases and skeletal-related events from neuroendocrine tumors
- Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions
- Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
- Metastatic Carcinoid Tumors: A Clinical Review